BOSTON , Aug. 27, 2024 /PRNewswire/ -- Glytec, a trailblazer in diabetes and insulin management software, announced today the expansion of its collaboration with Roche, a global pioneer in pharmaceuticals and diagnostics. The collaboration will allow the use of Glytec's software in connection with Roche's smart-device hospital blood glucose system, cobas ® pulse, in US and world-wide markets where both solutions are available.
Transforming Global Hospital Diabetes Management Glytec recognizes the significance of inpatient diabetes care and is committed to leveraging its expertise and innovative solutions to address this critical aspect of global healthcare delivery. Glytec's flagship insulin dosing decision support software, Glucommander ® , has received widespread recognition in the U.S.
for its effectiveness in addressing the challenges of inpatient diabetes care. Glytec's advanced analytics and decision support capabilities unlock valuable insights into treatment effectiveness, empowering healthcare providers to optimize glycemic management strategies and improve outcomes. A Commitment to Improved Patient Safety and Outcomes "Diabetes knows no borders, profoundly impacting hospital diabetes management and patient outcomes worldwide," said Robby Booth , Co-founder and Chief Strategy Officer at Glytec.
"We are proud of our expanded collaboration with Roche, which reaffirms our commitment to addressing this critical healthcare challenge for patients, providers, and payors a.